S&P Futures
4,299.50 +1.75 (+0.04%) Dow Futures
33,336.00 +10.00 (+0.03%) Nasdaq Futures
14,933.50 +9.75 (+0.07%) Russell 2000 Futures
1,745.10 +2.10 (+0.12%) Crude Oil
84.74 +0.52 (+0.62%) Gold
1,842.00 +7.20 (+0.39%)
Immunome, Inc. (IMNM)
After hours:
Chart Events
Performance Outlook
| Previous Close | 7.95 |
| Open | 7.93 |
| Bid | 7.40 x 1000 |
| Ask | 7.89 x 1000 |
| Day's Range | 7.55 - 7.93 |
| 52 Week Range | 2.20 - 9.24 |
| Volume | |
| Avg. Volume | 58,882 |
| Market Cap | 92.861M |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.14 |
| Earnings Date | Nov 13, 2023 - Nov 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for IMNM
Related Research
- Immunome, Inc.Daily – Vickers Top Insider Picks for 08/24/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat2 years agoArgus Research
- Business Wire
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
SEATTLE & EXTON, Pa., October 03, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it has completed its previously announced merger with Morphimmune.
Simply Wall St.Individual investors who hold 51% of Immunome, Inc. (NASDAQ:IMNM) gained 15%, institutions profited as well
Key Insights Immunome's significant individual investors ownership suggests that the key decisions are influenced by...
- Business Wire
Immunome Reports Second Quarter 2023 Financial Results
EXTON, Pa., August 09, 2023--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
